Fig. 2: Best response to the prior CAR-T and HRC0202. | Cancer Gene Therapy

Fig. 2: Best response to the prior CAR-T and HRC0202.

From: An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously

Fig. 2

(A) The chart shows different clinical response and their proportion to prior CAR-T and HRC0202. (B) The chart shows different patient and their best response to prior CAR-T and HRC0202. sCR stringent complete response, CR complete response, VGPR very good partial response, PR partial response, MR minimal response, NR no response, SD stable disease, PD progressive disease.

Back to article page